- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05949593
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy (PHOENIX)
March 17, 2024 updated by: Belite Bio, Inc
PHase 3, Multicenter, RandOmized, Double-masked, PlacEbo-CoNtrolled Study of TInlarebant to EXplore Safety and Efficacy in the Treatment of Geographic Atrophy (the PHOENIX Study)
This Phase 3, multicenter, double-masked, parallel-group, placebo-controlled, randomized, fixed-dose clinical study is designed to evaluate the efficacy and safety of tinlarebant (LBS-008) in subjects diagnosed with GA.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
Subjects will be randomized in a 2:1 ratio to receive either tinlarebant or placebo.
The study treatment will be administered orally once daily from baseline (Day 1) through the final day of Month 24.
Study Type
Interventional
Enrollment (Estimated)
429
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Belitebio Clinical Operations
- Phone Number: +886 972 080 097
- Email: clinicaltrial@belitebio.com
Study Locations
-
-
New South Wales
-
Chatswood, New South Wales, Australia, 2067
- Recruiting
- Belite Study Site
-
Strathfield, New South Wales, Australia, 2135
- Recruiting
- Belite Study Site
-
-
Queensland
-
Brisbane, Queensland, Australia, 4101
- Recruiting
- Belite Study Site
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Recruiting
- Belite Study Site
-
-
Victoria
-
East Melbourne, Victoria, Australia, 3002
- Recruiting
- Belite Study Site
-
East Melbourne, Victoria, Australia, 3002
- Not yet recruiting
- Belite Study Site
-
-
Western Australia
-
Crawley, Western Australia, Australia, 6009
- Recruiting
- Belite Study Site
-
-
-
-
Beijing
-
Beijing, Beijing, China, 100089
- Not yet recruiting
- Belite Study Site
-
-
Sichuan
-
Chengdu, Sichuan, China, 610093
- Not yet recruiting
- Belite Study Site
-
-
-
-
-
Taichung, Taiwan, 40447
- Not yet recruiting
- Belite Study Site
-
Taipei, Taiwan, 100
- Recruiting
- Belite Study Site
-
Taoyuan, Taiwan, 33305
- Recruiting
- Belite Study Site
-
-
-
-
-
Great Yarmouth, United Kingdom, NR31 6LA
- Not yet recruiting
- Belite Study Site
-
Harrow, United Kingdom, HA1 3UJ
- Recruiting
- Belite Study Site
-
London, United Kingdom, EC1V 2PD
- Not yet recruiting
- Belite Study Site
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85020
- Recruiting
- Belite Study Site
-
-
California
-
Arcadia, California, United States, 91007
- Not yet recruiting
- Belite Study Site
-
Beverly Hills, California, United States, 90211
- Recruiting
- Belite Study Site
-
Huntington Beach, California, United States, 92467
- Recruiting
- Belite Study Site
-
Los Angeles, California, United States, 90033
- Recruiting
- Belite Study Site
-
San Diego, California, United States, 92093
- Recruiting
- Belite Study Site
-
-
Maryland
-
Hagerstown, Maryland, United States, 21740
- Recruiting
- Belite Study Site
-
-
New York
-
Westbury, New York, United States, 11590
- Recruiting
- Belite Study Site
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Recruiting
- Belite Study Site
-
Wake Forest, North Carolina, United States, 27587
- Recruiting
- Belite Study Site
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Recruiting
- Belite Study Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107
- Recruiting
- Belite Study Site
-
Sewickley, Pennsylvania, United States, 15143
- Recruiting
- Belite Study Site
-
-
Tennessee
-
Germantown, Tennessee, United States, 38138
- Recruiting
- Belite Study Site
-
-
Texas
-
Abilene, Texas, United States, 79606
- Recruiting
- Belite Study Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subjects must have a confirmed diagnosis of GA with atrophic lesions in 1 or both eyes.
- Minimum BCVA is required in the study eye
Exclusion Criteria:
- The presence of diabetic macular edema or macular disease in either eye.
- Diabetic retinopathy more advanced than mild nonproliferative diabetic retinopathy, or any other retinal vascular disease in either eye.
- Uncontrolled diagnosed glaucoma in the study eye
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo tablets for tinlarebant 5 mg prepared similarly.
|
Experimental: LBS-008, Tinlarebant
|
5 mg tablet taken orally once a day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure the rate of change (growth rate slope) in geographic atrophy (GA) lesion size
Time Frame: From baseline to Month 24]
|
From baseline to Month 24]
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To measure the change in best-corrected visual acuity (BCVA) as assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) scale
Time Frame: From baseline to Month 24
|
From baseline to Month 24
|
To measure changes in the area and size of the inner/outer segment junction of photoreceptors by spectral domain optical coherence tomography (SD-OCT)
Time Frame: From baseline to Month 24
|
From baseline to Month 24
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To evaluate the correlation between the reduction of serum RBP4 and the growth of atrophic lesions (DDAF)
Time Frame: From baseline to Month 24
|
From baseline to Month 24
|
To measure changes in retinal sensitivity as assessed by microperimetry
Time Frame: From baseline to Month 24
|
From baseline to Month 24
|
To measure changes in contrast sensitivity as assessed using the Pelli-Robson Contrast Sensitivity Chart (or any assessment deemed acceptable by study sites)
Time Frame: From baseline to Month 24
|
From baseline to Month 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 27, 2023
Primary Completion (Estimated)
August 31, 2027
Study Completion (Estimated)
November 30, 2027
Study Registration Dates
First Submitted
July 10, 2023
First Submitted That Met QC Criteria
July 10, 2023
First Posted (Actual)
July 18, 2023
Study Record Updates
Last Update Posted (Actual)
March 19, 2024
Last Update Submitted That Met QC Criteria
March 17, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LBS-008-CT05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Geographic Atrophy
-
Aviceda Therapeutics, Inc.RecruitingMacular Degeneration | Geographic Atrophy of the MaculaUnited States
-
GlaxoSmithKlineCompletedAtrophy, GeographicUnited States, Canada
-
GlaxoSmithKlineQuintiles, Inc.Completed
-
Carl Zeiss Meditec, Inc.DataMed Devices Inc.CompletedAdvanced Dry AMD With Geographic AtrophyUnited States
-
Alkeus Pharmaceuticals, Inc.Active, not recruitingGeographic Atrophy | Age Related Macular Degeneration | AMD | Atrophy, GeographicUnited States
-
Apellis Pharmaceuticals, Inc.Active, not recruitingGeographic Atrophy Secondary to Age-related Macular DegenerationUnited States, Netherlands, France, Israel, Germany, United Kingdom, Canada, Czechia, Australia, Spain, Italy, Argentina, Brazil, New Zealand, Poland
-
IVERIC bio, Inc.Active, not recruitingMacular Degeneration | Geographic AtrophyUnited States, Latvia, France, Germany, Spain, Hungary, Canada, Israel, Argentina, Czechia, Colombia, Croatia, Italy
-
Boehringer IngelheimCompletedGeographic AtrophyUnited States
-
Genentech, Inc.Completed
-
Apellis Pharmaceuticals, Inc.CompletedGeographic AtrophyUnited States, Australia, New Zealand
Clinical Trials on Tinlarebant
-
RBP4 Pty LtdBelite Bio, IncCompleted
-
Belite Bio, IncActive, not recruitingStargardt Disease 1United States, Australia, Belgium, China, France, Germany, Hong Kong, Netherlands, Switzerland, Taiwan, United Kingdom
-
RBP4 Pty LtdBelite Bio, IncCompletedHealthy Volunteer | Dry Age-related Macular DegenerationAustralia